Literature DB >> 20062766

Pulmonary fibrosis associated with psychotropic drug therapy: a case report.

Clare Thornton1, Toby M Maher, David Hansell, Andrew G Nicholson, Athol U Wells.   

Abstract

INTRODUCTION: Sertraline and Risperidone are commonly used psychotropic drugs. Sertraline has previously been associated with eosinopilic pneumonia. Neither drug is recognised as a cause of diffuse fibrotic lung disease. Our report represents the first such case. CASE
PRESENTATION: We describe the case of a 33 year old Asian male with chronic schizophrenia who had been treated for three years with sertraline and risperidone. He presented to hospital in respiratory failure following a six month history of progressive breathlessness. High resolution CT scan demonstrated diffuse pulmonary fibrosis admixed with patchy areas of consolidation. Because the aetiology of this man's diffuse parenchymal lung disease remained unclear a surgical lung biopsy was undertaken. Histological assessment disclosed widespread fibrosis with marked eosinophillic infiltration and associated organising pneumonia - features all highly suggestive of drug induced lung disease. Following withdrawal of both sertraline and risperidone and initiation of corticosteroid therapy the patient's respiratory failure resolved and three years later he remains well albeit limited by breathlessness on heavy exertion.
CONCLUSION: Drug induced lung disease can be rapidly progressive and if drug exposure continues may result in respiratory failure and death. Prompt recognition is critical as drug withdrawal may result in marked resolution of disease. This case highlights sertraline and risperidone as drugs that may, in susceptible individuals, cause diffuse pulmonary fibrosis.

Entities:  

Year:  2009        PMID: 20062766      PMCID: PMC2803800          DOI: 10.1186/1752-1947-3-126

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  12 in total

Review 1.  Bronchoalveolar lavage in drug-induced lung disease.

Authors:  Ulrich Costabel; Esra Uzaslan; Josune Guzman
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

2.  [Interstitial lung disease linked to fluoxetine].

Authors:  L M Vandezande; C Lamblin; B Wallaert
Journal:  Rev Mal Respir       Date:  1997-09       Impact factor: 0.622

Review 3.  Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.

Authors:  Frank-Gerald Pajonk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-01       Impact factor: 5.067

Review 4.  Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.

Authors:  William D Travis; Gary Hunninghake; Talmadge E King; David A Lynch; Thomas V Colby; Jeffrey R Galvin; Kevin K Brown; Man Pyo Chung; Jean-François Cordier; Roland M du Bois; Kevin R Flaherty; Teri J Franks; David M Hansell; Thomas E Hartman; Ella A Kazerooni; Dong Soon Kim; Masanori Kitaichi; Takashi Koyama; Fernando J Martinez; Sonoko Nagai; David E Midthun; Nestor L Müller; Andrew G Nicholson; Ganesh Raghu; Moisés Selman; Athol Wells
Journal:  Am J Respir Crit Care Med       Date:  2008-04-03       Impact factor: 21.405

Review 5.  Interstitial lung disease induced by drugs and radiation.

Authors:  Philippe Camus; Annlyse Fanton; Philippe Bonniaud; Clio Camus; Pascal Foucher
Journal:  Respiration       Date:  2004 Jul-Aug       Impact factor: 3.580

Review 6.  Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

Authors:  T M Maher; A U Wells; G J Laurent
Journal:  Eur Respir J       Date:  2007-11       Impact factor: 16.671

Review 7.  Challenges in pulmonary fibrosis . 4: smoking-induced diffuse interstitial lung diseases.

Authors:  Athol U Wells; Andrew G Nicholson; David M Hansell
Journal:  Thorax       Date:  2007-10       Impact factor: 9.139

8.  Chronic eosinophilic pneumonia progressing to lung fibrosis.

Authors:  K Yoshida; N Shijubo; H Koba; Y Mori; M Satoh; T Morikawa; S Abe
Journal:  Eur Respir J       Date:  1994-08       Impact factor: 16.671

9.  Fluoxetin-induced pulmonary granulomatosis.

Authors:  E de Kerviler; J Trédaniel; G Revlon; O Groussard; G Zalcman; J M Ortoli; M Espié; A Hirsch; J Frija
Journal:  Eur Respir J       Date:  1996-03       Impact factor: 16.671

10.  Acute eosinophilic pneumonia associated with antidepressant agents.

Authors:  M T Barnés; J Bascuñana; B García; J L Alvarez-Sala
Journal:  Pharm World Sci       Date:  1999-10
View more
  4 in total

1.  Aripiprazole-induced hypersensitivity pneumonitis.

Authors:  Kulothungan Gunasekaran; Swetha Murthi; Jeffrey Jennings; Nazir Lone
Journal:  BMJ Case Rep       Date:  2017-05-09

Review 2.  Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

3.  Sertraline-induced hypersensitivity pneumonitis.

Authors:  Gursharan Virdee; John Bleasdale; Mohammed Ikramullah; Emma Graham-Clarke
Journal:  BMJ Case Rep       Date:  2019-12-19

4.  The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-control study.

Authors:  Ted Rosenberg; Rory Lattimer; Patrick Montgomery; Christian Wiens; Liran Levy
Journal:  Clin Interv Aging       Date:  2017-11-21       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.